Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients

Research by: T. Fairhead(1), E. Hendren(2), K. Tinckam(3), C. Rose(2), C.H. Sherlock(4), L. Shi(5), N.S. Crowcroft(5), J.B. Gubbay(5), D. Landsberg(2), G. Knoll(1), J. Gill(2), D. Kumar(6) of (1) Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada, (2) the Division of Nephrology, The University of British Columbia, Vancouver, British Columbia, Canada, (3) the Laboratory Medicine Program and Division of Nephrology, University Health Network, Toronto, Ontario, Canada, (4) the Departments of Pathology and Laboratory Medicine, The University of British Columbia and Providence Health Care, Vancouver, British Columbia, Canada, (5) Public Health Ontario, Toronto, Ontario, Canada, and (6) the Alberta Institute for Transplant Sciences, University of Alberta, Edmonton, Alberta, Canada.

Journal: Transplant Infectious Disease

Immunization is impaired in immunosuppressed individuals. This study demonstrated a dramatic impact of routine post-transplant immunosuppression on seroprotection after pH1N1 vaccination leaving approximately 2/3 without seroprotection. Importantly, 11.9% of vaccinated patients demonstrated new anti-HLA antibodies post vaccination. The authors inform future research into how to improve seroprotection without adversely affecting HLA antibody formation.

Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients (PDF)